Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 120

1.

Activation of HIF1alpha ubiquitination by a reconstituted von Hippel-Lindau (VHL) tumor suppressor complex.

Kamura T, Sato S, Iwai K, Czyzyk-Krzeska M, Conaway RC, Conaway JW.

Proc Natl Acad Sci U S A. 2000 Sep 12;97(19):10430-5.

2.

A molecular basis for stabilization of the von Hippel-Lindau (VHL) tumor suppressor protein by components of the VHL ubiquitin ligase.

Kamura T, Brower CS, Conaway RC, Conaway JW.

J Biol Chem. 2002 Aug 16;277(33):30388-93. Epub 2002 Jun 4.

3.

Mechanism of regulation of the hypoxia-inducible factor-1 alpha by the von Hippel-Lindau tumor suppressor protein.

Tanimoto K, Makino Y, Pereira T, Poellinger L.

EMBO J. 2000 Aug 15;19(16):4298-309.

4.

Role of exon 2-encoded beta -domain of the von Hippel-Lindau tumor suppressor protein.

Bonicalzi ME, Groulx I, de Paulsen N, Lee S.

J Biol Chem. 2001 Jan 12;276(2):1407-16.

5.

Hypoxia inducible factor-alpha binding and ubiquitylation by the von Hippel-Lindau tumor suppressor protein.

Cockman ME, Masson N, Mole DR, Jaakkola P, Chang GW, Clifford SC, Maher ER, Pugh CW, Ratcliffe PJ, Maxwell PH.

J Biol Chem. 2000 Aug 18;275(33):25733-41.

6.

VHL takes HIF's breath away.

Krek W.

Nat Cell Biol. 2000 Jul;2(7):E121-3.

PMID:
10878820
8.

The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis.

Maxwell PH, Wiesener MS, Chang GW, Clifford SC, Vaux EC, Cockman ME, Wykoff CC, Pugh CW, Maher ER, Ratcliffe PJ.

Nature. 1999 May 20;399(6733):271-5.

PMID:
10353251
9.

Ubiquitination of hypoxia-inducible factor requires direct binding to the beta-domain of the von Hippel-Lindau protein.

Ohh M, Park CW, Ivan M, Hoffman MA, Kim TY, Huang LE, Pavletich N, Chau V, Kaelin WG.

Nat Cell Biol. 2000 Jul;2(7):423-7.

PMID:
10878807
11.

Identification of Elongin C and Skp1 sequences that determine Cullin selection.

Yan Q, Kamura T, Cai Y, Jin J, Ivan M, Mushegian A, Conaway RC, Conaway JW.

J Biol Chem. 2004 Oct 8;279(41):43019-26. Epub 2004 Jul 27.

12.
13.

In vitro and in vivo models analyzing von Hippel-Lindau disease-specific mutations.

Rathmell WK, Hickey MM, Bezman NA, Chmielecki CA, Carraway NC, Simon MC.

Cancer Res. 2004 Dec 1;64(23):8595-603.

14.
15.

Molecular cloning and characterization of the von Hippel-Lindau-like protein.

Qi H, Gervais ML, Li W, DeCaprio JA, Challis JR, Ohh M.

Mol Cancer Res. 2004 Jan;2(1):43-52.

16.

The von Hippel-Lindau tumor suppressor gene.

Kondo K, Kaelin WG Jr.

Exp Cell Res. 2001 Mar 10;264(1):117-25. Review.

PMID:
11237528
17.

Identification of the von Hippel-lindau tumor-suppressor protein as part of an active E3 ubiquitin ligase complex.

Iwai K, Yamanaka K, Kamura T, Minato N, Conaway RC, Conaway JW, Klausner RD, Pause A.

Proc Natl Acad Sci U S A. 1999 Oct 26;96(22):12436-41.

18.

Expression of HIF-1 and ubiquitin in conventional renal cell carcinoma: relationship to mutations of the von Hippel-Lindau tumor suppressor gene.

Hughson MD, He Z, Liu S, Coleman J, Shingleton WB.

Cancer Genet Cytogenet. 2003 Jun;143(2):145-53.

PMID:
12781449
19.
20.

Regulation of STRA13 by the von Hippel-Lindau tumor suppressor protein, hypoxia, and the UBC9/ubiquitin proteasome degradation pathway.

Ivanova AV, Ivanov SV, Danilkovitch-Miagkova A, Lerman MI.

J Biol Chem. 2001 May 4;276(18):15306-15. Epub 2001 Feb 6.

Supplemental Content

Support Center